|
||
Ciprofloxacin 1A Pharma Pregnancy |
||
Contraindicated in pregnancy (safety and efficacy in women during pregnancy has not been established); Ciprofloxacin 1A Pharma crosses the placenta, excreted in breast milk.
In experimental studies found that it causes arthropathy. In experiments on rats and mice treated with Ciprofloxacin 1A Pharma in doses exceeding the usual daily dose for a person 6 times, adverse effects on the fetus is not revealed. In experiments on rabbits treated with oral dose of Ciprofloxacin 1A Pharma 30 and 100 mg / kg, it is shown that the drug causes disruption of the gastrointestinal tract, leading to loss of body weight in females and increase the number of miscarriages but teratogenicity not found. When IV introduction to the doses of 20 mg / kg Ciprofloxacin 1A Pharma did not exert toxic effects on the mother and embryo, showed no teratogenicity. The use of local forms of Ciprofloxacin 1A Pharma in pregnancy is possible if the anticipated benefits exceed the potential risk to the fetus.
Category of the fetus by FDA - C.
Ciprofloxacin 1A Pharma is excreted in breast milk, so the period of lactation should decide, stop taking Ciprofloxacin 1A Pharma or breastfeeding based on the degree of importance of the use of drugs for the mother.
With careful use of local forms of Ciprofloxacin 1A Pharma in breast-feeding (not known whether Ciprofloxacin 1A Pharma is excreted in breast milk when applied topically).
There are no data on the excretion of Ciprofloxacin 1A Pharma otic into human milk. Concentrations of orally administered Ciprofloxacin 1A Pharma found in breast milk have ranged from 85% (at 24 hours post dose) to 214% (at 4 hours post dose) of maternal serum concentration. In one case report, an infant developed perforated pseudomembranous colitis following ingestion of Ciprofloxacin 1A Pharma via the mother's milk. In addition, quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. However, limited data indicate that systemic absorption after otic administration is extremely low. Plasma levels of Ciprofloxacin 1A Pharma and hydrocortisone are expected to be below the level of quantitation after administration of 3 drops of suspension into the ear. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or to discontinue nursing, taking into account the importance of the drug to the mother.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|